drugset / Trial / NCT07846020
Mechanistic Evaluation of Polypharmacy Effects for Pain
Phase 1/2
Not yet recruiting
110 enrolled
University of Maryland, Baltimore
National Institute on Drug Abuse (NIDA) · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
This is a single-group, within-subject, double-blind, double-dummy, placebo-controlled study evaluating whether gabapentin (Neurontin) changes the analgesic, safety, and subjective effects of the opioid hydromorphone (Dilaudid) when the two are combined.
Timeline
- Start
- 2027-01-15
- Primary completion
- 2032-01-15
- Completion
- 2032-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gabapentin | Unknown | 300 mg | Oral |
| Subject | Gabapentin | Unknown | 900 mg | Oral |
| Subject | Hydromorphone | Other / unclassified | 4 mg | Oral |